Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced results for its fiscal 2013 third quarter.
Revenue and Earnings Summary
Revenue for the third quarter totaled $14.3 million, a 2% increase from $14.0 million reported in the fiscal 2012 third quarter. Diluted earnings per share from continuing operations totaled $0.22 compared with $0.18 in the prior-year period.
Help employers find you! Check out all the jobs and post your resume.
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced results for its fiscal 2013 third quarter.
Revenue and Earnings Summary
Revenue for the third quarter totaled $14.3 million, a 2% increase from $14.0 million reported in the fiscal 2012 third quarter. Diluted earnings per share from continuing operations totaled $0.22 compared with $0.18 in the prior-year period.
Help employers find you! Check out all the jobs and post your resume.
